Ilan Ben-Zvi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6779007/publications.pdf

Version: 2024-02-01

394421 276875 1,915 75 19 41 citations h-index g-index papers 78 78 78 3061 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical and prognostic significance of elevated ferritin levels in hospitalised adults. Postgraduate Medical Journal, 2022, 98, 622-625.	1.8	2
2	Safety of the BNT162b2 mRNA COVID-19 vaccine in patients with familial Mediterranean fever. Rheumatology, 2022, 61, SI129-SI135.	1.9	6
3	The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease. International Journal of Molecular Sciences, 2022, 23, 3956.	4.1	2
4	Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. European Journal of Preventive Cardiology, 2022, 29, 1334-1342.	1.8	16
5	Physiological Effects of Wearing N95 Respirator on Medical Staff During Prolong Work Hours in Covid-19 Departments. Journal of Occupational and Environmental Medicine, 2022, 64, e378-e380.	1.7	6
6	CHA2DS2-VASC Score Predicts the Risk of Stroke in Patients Hospitalized to the Internal Medicine Department Without Known Atrial Fibrillation. Journal of General Internal Medicine, 2022, 37, 3355-3360.	2.6	0
7	Automated processing of thermal imaging to detect COVID-19. Scientific Reports, 2021, 11, 17489.	3.3	25
8	Familial Mediterranean fever (FMF)-response to TNF-blockers used for treatment of FMF patients with concurrent inflammatory diseases. Joint Bone Spine, 2021, 88, 105201.	1.6	4
9	Amyloid storm: acute kidney injury and massive proteinuria, rapidly progressing to end-stage kidney disease in AA amyloidosis of familial Mediterranean fever. Rheumatology, 2021, 60, 3235-3242.	1.9	9
10	Adult Still's Disease Triggered by Influenza Vaccine. Israel Medical Association Journal, 2021, 23, 196-197.	0.1	2
11	Effect of interleukin-1 inhibition in a cohort of patients with colchicine-resistant familial Mediterranean fever treated consecutively with anakinra and canakinumab. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 75-79.	0.8	0
12	Effect of interleukin-1 inhibition in a cohort of patients with colchicine-resistant familial Mediterranean fever treated consecutively with anakinra and canakinumab. Clinical and Experimental Rheumatology, 2021, 39, 75-79.	0.8	4
13	Macrophage activation syndrome complicating rheumatic diseases in adults: case-based review. Rheumatology International, 2020, 40, 663-669.	3.0	17
14	IFNγ potentiates TNFα/TNFR1 signaling to induce FAT10 expression in macrophages. Molecular Immunology, 2020, 117, 101-109.	' 2.2	8
15	Saliva immunoglobulin free light chain analysis for monitoring disease activity and response to treatment in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 44, 102339.	2.0	8
16	Environmental shedding of toxigenic Clostridioides difficile by asymptomatic carriers: A prospective observational study. Clinical Microbiology and Infection, 2020, 26, 1052-1057.	6.0	20
17	Kidney disease and plasma cell dyscrasias: ambiguous cases solved by serum free light chain dimerization analysis. Clinical and Experimental Nephrology, 2019, 23, 763-772.	1.6	2
18	Clinical significance of positive antiâ€neutrophil cytoplasmic antibodies without evidence of antiâ€neutrophil cytoplasmic antibodiesâ€associated vasculitis. International Journal of Rheumatic Diseases, 2019, 22, 940-945.	1.9	14

#	Article	IF	Citations
19	Type 2 myocardial infarction in general medical wards. Medicine (United States), 2019, 98, e17404.	1.0	23
20	Familial Mediterranean fever (FMF) phenotype in patients homozygous to the MEFV M694V mutation. European Journal of Medical Genetics, 2019, 62, 103532.	1.3	39
21	Efficacy and safety of long-term treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine. Rheumatology International, 2019, 39, 517-523.	3.0	11
22	Cytokine expression in temporal arteries: comparative analysis between patients with biopsy-positive giant cell arteritis, biopsy-negative giant cell arteritis and biopsy-negative without arteritis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 122-129.	0.8	1
23	Reply. Arthritis and Rheumatology, 2018, 70, 1167-1168.	5. 6	O
24	Negative temporal artery biopsy: predictive factors for giant cell arteritis diagnosis and alternate diagnoses of patients without arteritis. Clinical Rheumatology, 2018, 37, 2819-2824.	2.2	16
25	Left Ventricular Hypertrophy Predicts Cardiovascular Events in Hypertensive Patients With Coronary Artery Calcifications. American Journal of Hypertension, 2018, 31, 313-320.	2.0	14
26	Colchicine intoxication in familial Mediterranean fever patients using clarithromycin for the treatment of Helicobacter pylori: a series of six patients. Rheumatology International, 2018, 38, 141-147.	3.0	17
27	Familial Mediterranean Fever and Incidence of Cancer. Arthritis and Rheumatology, 2018, 70, 127-133.	5.6	27
28	Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis. Clinical and Experimental Immunology, 2018, 192, 7-17.	2.6	10
29	Toll-like receptor 2 is overexpressed in Familial Mediterranean fever patients and is inhibited by colchicine treatment. Best Practice and Research in Clinical Rheumatology, 2018, 32, 651-661.	3.3	10
30	DNA-Mediated Interferon Signature Induction by SLE Serum Occurs in Monocytes Through Two Pathways: A Mechanism to Inhibit Both Pathways. Frontiers in Immunology, 2018, 9, 2824.	4.8	32
31	Analysis of microRNAs in familial Mediterranean fever. PLoS ONE, 2018, 13, e0197829.	2.5	22
32	Hematological malignancies mimicking rheumatic syndromes: case series and review of the literature. Rheumatology International, 2018, 38, 1743-1749.	3.0	8
33	The prevalence and clinical effect of immunogenicity of TNF- \hat{l}_{\pm} blockers in patients with axial spondyloarthritis. Clinical and Experimental Rheumatology, 2018, 36, 228-232.	0.8	8
34	Inflammation and cardiovascular disease in familial Mediterranean fever. An analysis of hospital admissions for acute cardiovascular event. Clinical and Experimental Rheumatology, 2018, 36, 80-85.	0.8	9
35	Effect of tumor necrosis factor-α inhibitors on ambulatory 24-h blood pressure. Blood Pressure, 2017, 26, 24-29.	1.5	8
36	Factors associated with suitability of empiric antibiotic therapy in hospitalized patients with bloodstream infections. Journal of Chemotherapy, 2017, 29, 159-163.	1.5	3

#	Article	IF	Citations
37	Gender disparities in the functional significance of anemia among apparently healthy adults. European Journal of Haematology, 2017, 98, 435-442.	2.2	5
38	Reply. Arthritis and Rheumatology, 2017, 69, 1914-1914.	5.6	0
39	Association between specimen length and diagnostic yield of temporal artery biopsy. Scandinavian Journal of Rheumatology, 2017, 46, 222-225.	1.1	16
40	Anakinra for Colchicineâ€Resistant Familial Mediterranean Fever: A Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Arthritis and Rheumatology, 2017, 69, 854-862.	5.6	147
41	Normal arterial stiffness in familial Mediterranean fever. Evidence for a possible cardiovascular protective role of colchicine. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 32-37.	0.8	3
42	Risk factors for severe cranial ischaemic events in patients with giant cell arteritis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 88-93.	0.8	5
43	Carriage of Mediterranean Fever (MEFV) Mutations in Patients with Postpericardiotomy Syndrome (PPS). Israel Medical Association Journal, 2017, 19, 562-565.	0.1	1
44	The impact of inflammatory rheumatic diseases on the presentation, severity, and outcome of acute coronary syndrome. Clinical Rheumatology, 2016, 35, 233-237.	2.2	10
45	Baseline clinical predictors of an ultimate giant cell arteritis diagnosis in patients referred to temporal artery biopsy. Clinical Rheumatology, 2016, 35, 1817-1822.	2.2	24
46	Familial Mediterranean fever without MEFV mutations: a case–control study. Orphanet Journal of Rare Diseases, 2015, 10, 34.	2.7	51
47	Cardiovascular and Metabolic Risk Factors in Inherited Autoinflammation. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2123-E2128.	3.6	16
48	Colchicine-free remission in familial Mediterranean fever: featuring a unique subset of the disease-a case control study. Orphanet Journal of Rare Diseases, 2014, 9, 3.	2.7	23
49	Serum Uric Acid Is Associated With Coronary Artery Calcification. Journal of Clinical Hypertension, 2014, 16, 424-428.	2.0	17
50	Exertional Leg Pain in Familial Mediterranean Fever: A Manifestation of an Underlying Enthesopathy and a Marker of More Severe Disease. Arthritis and Rheumatology, 2014, 66, 3221-3226.	5.6	31
51	Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Annals of the Rheumatic Diseases, 2014, 73, 704-709.	0.9	70
52	Immunoglobulinâ€free light chain monomerâ€dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: A pilot study. American Journal of Hematology, 2014, 89, 882-888.	4.1	23
53	Anti-DNA antibodies cross-react with C1q. Journal of Autoimmunity, 2013, 44, 34-39.	6.5	27
54	E148Q MEFV mutation carriage and longevity in individuals of Ashkenazi origin. Immunologic Research, 2013, 56, 371-375.	2.9	5

#	Article	IF	CITATIONS
55	Familial Mediterranean Fever (FMF) with Proteinuria: Clinical Features, Histology, Predictors, and Prognosis in a Cohort of 25 Patients. Journal of Rheumatology, 2013, 40, 2083-2087.	2.0	27
56	T helper 17 polarization in familial Mediterranean fever. Genes and Immunity, 2013, 14, 212-216.	4.1	18
57	Exertional muscle pain in familial Mediterranean fever patients evaluated by MRI and 31P magnetic resonance spectroscopy. Clinical Radiology, 2013, 68, 371-375.	1.1	6
58	â€~Silent' carriage of two familial Mediterranean fever gene mutations in large families with only a single identified patient. Clinical Genetics, 2012, 82, 288-291.	2.0	17
59	Exertional leg pain as a manifestation of occult spondyloarthropathy in familial Mediterranean fever: an MRI evaluation. Scandinavian Journal of Rheumatology, 2012, 41, 482-486.	1.1	12
60	The relative contribution of environmental and genetic factors to phenotypic variation in familial Mediterranean fever (FMF). Gene, 2012, 491, 260-263.	2.2	42
61	Environment, Immune Dysfunction, and Systemic Lupus Erythematosus. Molecular and Integrative Toxicology, 2012, , 193-213.	0.5	0
62	Hydroxychloroquine: From Malaria to Autoimmunity. Clinical Reviews in Allergy and Immunology, 2012, 42, 145-153.	6.5	465
63	QT dispersion in amyloidosis due to familial Mediterranean fever. Rheumatology International, 2012, 32, 1945-1948.	3.0	14
64	Normal QT dispersion in colchicine-resistant familial Mediterranean fever (FMF). Clinical Rheumatology, 2012, 31, 1093-1096.	2.2	18
65	Sex and Gender Differences in Autoimmune Diseases. , 2012, , 101-124.		5
66	The Israeli Annual FMF, Amyloidosis and Other Autoinflammatory Diseases Meeting (July 2011): a bridge spanning these entities. Israel Medical Association Journal, 2012, 14, 219-20.	0.1	0
67	Risk factors for amyloidosis and impact of kidney transplantation on the course of familial Mediterranean fever. Israel Medical Association Journal, 2012, 14, 221-4.	0.1	9
68	Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nature Reviews Rheumatology, 2011, 7, 105-112.	8.0	181
69	P-wave dispersion in systemic AA amyloidosis of familial Mediterranean fever. Clinical Rheumatology, 2011, 30, 1295-1298.	2.2	9
70	First Detection of Human Infection With Rickettsia felis in Israel. American Journal of the Medical Sciences, 2010, 340, 343-344.	1.1	14
71	The Impact of Vitamin D on Dendritic Cell Function in Patients with Systemic Lupus Erythematosus. PLoS ONE, 2010, 5, e9193.	2.5	138
72	Benzodiazepine and opioid sedation attenuate the sympathetic response to fiberoptic bronchoscopy. Prophylactic labetalol gave no additional benefit. Results of a randomized double-blind placebo-controlled study. Respiratory Medicine, 2008, 102, 978-983.	2.9	22

#	Article	IF	CITATIONS
73	A Case of Murine Typhus Associated With Large Vessel Infarct of the Spleen. American Journal of the Medical Sciences, 2008, 335, 502-503.	1.1	8
74	Effects of Diabetes Mellitus, Chronic Renal Failure and Hemodialysis on Serum and Salivary Antioxidant Status. Nephron Clinical Practice, 2007, 105, c114-c120.	2.3	19
75	Salivary \hat{I}^2 2-Microglobulin Analysis in Chronic Kidney Disease and Hemodialyzed Patients. Blood Purification, 2007, 25, 505-509.	1.8	12